Senior appointment for Ipsen

Steven Hildemann has been named as the new Executive Vice President, Chief Medical Officer and Head of Global Medical Affairs and Pharmacovigilance at French pharma firm, Ipsen.

Prior, Dr. Hildemann held leadership roles in science-based bioethics and built an innovative digital health start-up in cancer care after serving for five years at Merck.

He also held several strategic leadership positions with biopharmaceutical companies such as Pharmacia-Pfizer and Schering-Plough-MSD.

In his new role, he will act as a strategic partner to Ipsen’s scientific, clinical and business teams. He will provide a global medical strategy based on real value to patients and caregivers.

In close partnership with R&D, Dr. Hildemann will lead the generation of post-launch clinical trial data by defining, prioritizing, optimizing or guiding studies in line with this strategy.

As a member of the Executive Leadership team, he will actively contribute to the overall management and strategic leadership of the company.

The appointment is effective March 1.

A message from the Editor:

Thank you for reading this story on our news site - please take a moment to read this important message:

As you know, our aim is to bring you, the reader, an editorially led news site but journalism costs money and we rely on advertising and digital revenues to help to support them.

With the Covid-19 lockdown having a major impact on our industry as a whole, the advertising revenues we normally receive, which helps us cover the cost of our journalists and this website, have been drastically affected.

As such we need your help. If you can support our news sites with a small donation of even £1, your generosity will help us weather the storm and continue in our quest to deliver quality journalism.

In the meantime may I wish you the very best.

- Advertisement -

Related news